Last 33 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.56 | — | — | 0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | 4.77 | 1.03 | 0.32 | — | 83.04 | 6.56 | 3.15 | 2.68 | 0.75 | 0.69 | 0.61 | 0.51 | 0.49 | 0.62 | 0.62 | 0.23 | 0.45 | 0.65 | 1.75 | 3.17 |
| — | -94.3% | -84.3% | -89.7% | — | +11039.5% | +853.8% | +411.7% | +430.7% | +53.4% | +10.6% | -0.9% | +121.0% | +7.3% | -3.7% | -64.6% | -92.8% | -97.8% | -94.1% | -74.2% | -33.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | -0.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -29.7% | -121.6% | 229.1% | — | -210.1% | -105.9% | -61.7% | -33.2% | -12.0% | -59.0% | -14.0% | -10.6% | -6.3% | -5.5% | -12.8% | -5.4% | -7.3% | -15.2% | -19.2% | -18.6% |
| — | +85.8% | -14.9% | +471.4% | — | -1658.0% | -79.3% | -340.6% | -213.8% | -89.9% | -969.9% | -9.0% | -96.0% | +14.1% | +63.7% | +33.2% | +71.0% | +53.6% | -4.3% | -37.0% | -63.2% | |
| ROA | -80.7% | -24.1% | -100.2% | 59.8% | -38.8% | -11.8% | -14.3% | -13.6% | -10.3% | -4.2% | -20.6% | -6.6% | -6.7% | -6.1% | -5.4% | -12.4% | -5.2% | -7.0% | -14.2% | -17.4% | -16.7% |
| — | -103.4% | -600.5% | +540.6% | -275.2% | -181.7% | +30.4% | -106.6% | -54.4% | +31.6% | -283.4% | +47.1% | -29.3% | +11.7% | +62.1% | +28.4% | +68.9% | +50.5% | -9.3% | -36.8% | -59.9% | |
| ROIC | -482.0% | -72.5% | — | — | — | -80.6% | -38.1% | -34.1% | -15.7% | -7.9% | -39.6% | -11.6% | -9.0% | -7.3% | -7.7% | -19.4% | -7.3% | -8.3% | -23.4% | -36.8% | -29.0% |
| — | +10.1% | — | — | — | -918.6% | +3.7% | -193.3% | -75.5% | -9.0% | -410.6% | +40.0% | -22.5% | +12.2% | +66.9% | +47.3% | +74.8% | +64.3% | -0.4% | -86.6% | -113.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.03 | — | 16.99 | 1.49 | 0.85 | 0.49 | 0.34 | 0.31 | 0.19 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| — | — | — | -96.9% | — | +4841.2% | +386.7% | +346.2% | +202.6% | +46746.5% | +17996.2% | +6270.4% | +3505.5% | -81.7% | -64.0% | -6.4% | -54.0% | -60.4% | -13.7% | +35.5% | +278.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.53 | 14.72 | 14.52 | 2.92 | 0.53 | 1.12 | 5.00 | 4.05 | 6.05 | 9.53 | 6.15 | 7.16 | 8.09 | 37.80 | 45.36 | 29.69 | 30.55 | 19.87 | 16.70 | 9.92 | 7.85 |
| — | +1213.2% | +190.3% | -27.9% | -91.2% | -88.2% | -18.6% | -43.5% | -25.2% | -74.8% | -86.5% | -75.9% | -73.5% | +90.2% | +171.6% | +199.2% | +289.0% | +135.5% | +127.9% | +18.3% | -3.2% | |
| Quick Ratio | 0.53 | 14.72 | 14.52 | 2.92 | 0.53 | 1.12 | 5.00 | 4.05 | 6.05 | 9.53 | 6.15 | 7.16 | 8.09 | 37.80 | 45.36 | 29.69 | 30.55 | 19.87 | 16.70 | 9.92 | 7.85 |
| — | +1213.2% | +190.3% | -27.9% | -91.2% | -88.2% | -18.6% | -43.5% | -25.2% | -74.8% | -86.5% | -75.9% | -73.5% | +90.2% | +171.6% | +199.2% | +289.0% | +135.5% | +127.9% | +18.3% | -3.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRLA stock.
IRulya Therapeutics Inc.'s current P/E is -4.6x. The average P/E over the last 1 quarters is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IRulya Therapeutics Inc.'s business trajectory between earnings reports.